1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,800 | 7,450 | 13:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | EUPRAXIA PHARMACEUTICALS INC. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 15.01. | Cantor Fitzgerald raises Eupraxia Pharmaceuticals stock price target to $19 | 2 | Investing.com | ||
| 08.01. | Eupraxia Trial Data Shows Lasting Tissue Healing In Patients With Inflamed Esophagus | 1 | Benzinga.com | ||
| 08.01. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 08.01. | Eupraxia meldet positive Daten aus Studie zur Behandlung von EoE | 1 | Investing.com Deutsch | ||
| 08.01. | Eupraxia reports positive data from EoE treatment trial | 3 | Investing.com | ||
| 08.01. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy | 183 | GlobeNewswire (Europe) | At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete improvement in tissue health1- At lower doses, patients maintained the improvements... ► Artikel lesen | |
| EUPRAXIA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 14.11.25 | Cantor Fitzgerald reiterates Overweight rating on Eupraxia stock at $11 | 1 | Investing.com | ||
| 14.11.25 | Eupraxia: Cantor Fitzgerald bestätigt "Overweight"-Rating und sieht 73 % Kurspotenzial | 1 | Investing.com Deutsch | ||
| 13.11.25 | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI | 211 | GlobeNewswire (Europe) | The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability data previously reported from Cohort 5; Cohorts 5 & 6 are the only groups to reach 52 weeks thus... ► Artikel lesen | |
| 13.11.25 | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 05.11.25 | Eupraxia Pharmaceuticals Inc: Eupraxia Pharmaceuticals ends Q3 with cash of $89M | 1 | Stockwatch | ||
| 04.11.25 | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results | 86 | GlobeNewswire (Europe) | Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by... ► Artikel lesen | |
| 04.11.25 | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 30.10.25 | This analyst loves Eupraxia Pharmaceuticals | 1 | Cantech Letter | ||
| 02.10.25 | H.C. Wainwright bestätigt Kaufempfehlung für Eupraxia nach starken Studiendaten | 1 | Investing.com Deutsch | ||
| 02.10.25 | H.C. Wainwright reiterates Buy rating on Eupraxia Pharmaceuticals stock | 1 | Investing.com | ||
| 30.09.25 | Eupraxia Reports Encouraging Safety And Efficacy Data From Eosinophilic Esophagitis Study | 1 | Benzinga.com | ||
| 30.09.25 | Eupraxia Pharmaceuticals stock maintains Overweight rating at Cantor Fitzgerald | 3 | Investing.com | ||
| 29.09.25 | Eupraxia reports positive data from highest dose cohort in EoE trial | 1 | Investing.com |
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 1,410 | +0,71 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,568 | +2,10 % | PacBio Completes Sale of Short-Read Sequencing Assets | MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of... ► Artikel lesen | |
| EXACT SCIENCES | 87,17 | 0,00 % | Exact Sciences ticks higher amid reports HSR for Abbott deal expired | ||
| ARBUTUS BIOPHARMA | 3,150 | -3,37 % | Arbutus Biopharma Corp - 8-K, Current Report | ||
| XOMA ROYALTY | 20,600 | -7,21 % | XOMA Royalty Corporation: XOMA Royalty Announces CFO Transition | EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (Nasdaq: XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,352 | -0,44 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC | - Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in... ► Artikel lesen | |
| IMMUNIC | 0,511 | -1,73 % | EQS-News: Immunic AG: Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis | Issuer: Immunic AG
/ Key word(s): Conference/Study results
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 2,114 | -1,45 % | Iovance Biotherapeutics, Inc.: Best-in-Class Real-World Data Support Early Amtagvi Treatment in Advanced Melanoma | SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal... ► Artikel lesen | |
| GUARDANT HEALTH | 84,70 | -1,63 % | Krebs-Impfstoff: Chance Teil 2: Phase-2-Start für den Brustkrebs-Impfstoff und starke CAR-T-Daten bei Eierstockkrebs.Wird 2026 der Wendepunkt? | ||
| CYTOKINETICS | 52,50 | -0,94 % | Cytokinetics stock maintains Buy rating at B.Riley amid strong CMI market | ||
| COHERUS ONCOLOGY | 1,747 | -3,29 % | Coherus Biosciences stock gains on JNJ clinical supply agreement | ||
| CURIS | 0,840 | -4,00 % | Curis, Inc.: Curis Provides Third Quarter 2025 Business Update | Management to host conference call and webcast today at 4:30 p.m. ET
LEXINGTON, Mass., Nov. 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology... ► Artikel lesen | |
| FATE THERAPEUTICS | 0,928 | -3,35 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | ||
| AGENUS | 2,460 | -1,60 % | Agenus Inc.: Agenus meldet Abschluss einer strategischen Kooperationsvereinbarung mit Zydus Lifesciences im Wert von 141 Millionen US-Dollar zur Weiterentwicklung von BOT+BAL und Stärkung der Produktionskapazitäten in den USA | Agenus Inc. (Nasdaq: AGEN), ein führendes Unternehmen auf dem Gebiet der Immunonkologie, gab heute den Abschluss seiner bereits angekündigten strategischen Zusammenarbeit mit Zydus Lifesciences... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 2,678 | +0,34 % | Rocket Pharma cut at J.P. Morgan on risks to Danon disease program |
Das Unternehmen EUPRAXIA PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -6,16 % bei einem Aktienkurs von 6,850 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EUPRAXIA PHARMACEUTICALS INC finden Sie auf Wallstreet Online.